Zimstat (simvastatin) 5 mg Tablets Shortage and Substitution Approval Extended

What Happened

The Therapeutic Goods Administration (TGA) has announced an extension of the Serious Scarcity Substitution Instrument (SSSI) for Zimstat (simvastatin) 5 mg tablets. This regulatory action was taken in response to an ongoing shortage of the medication to ensure patients can still access treatment.

Which Products Are Affected

The affected product is Zimstat (simvastatin) 5 mg tablets. The shortage pertains to the supply of this specific dosage form within the Australian market.

What You Should Do

Patients who rely on Zimstat 5 mg tablets should consult with their healthcare provider or pharmacist. The extension of the SSSI allows pharmacists to provide a substitute medicine under specific conditions without requiring a new prescription from a doctor, helping to manage the impact of the scarcity.

Why This Matters

This extension is significant as it provides a legal framework for pharmacists to ensure continuity of care for patients requiring simvastatin while the primary brand remains in short supply.

Source

TGA Medicine Shortage Alert - Therapeutic Goods Administration